# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2019 Earnings Results

**Report date:** 2020-02-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2019

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.75%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.50 | N/A | +6.92% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed confidence in the company's current trajectory and product pipeline. They are focused on long-term growth despite not providing specific guidance.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining a robust pipeline for future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and possibly strong sales in their key products. The stock's 4.75% increase reflects investor confidence in the company's future potential. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial outlook.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2019_